Pownall Henry J, Gotto Antonio M
HOUSTON METHODIST RESEARCH INSTITUTE, HOUSTON, TEXAS; WEILL CORNELL MEDICINE, NEW YORK, NEW YORK.
Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):9-15. doi: 10.14797/mdcj-15-1-9.
Given its role in many biochemical processes essential to life, cholesterol remains a topic of intense research. Of all the plasma lipids, cholesterol is distinctive because it is a precursor to steroidogenic molecules, some of which regulate metabolism, and its blood concentration in the form of low- and high-density lipoprotein cholesterol (HDL-C) are positive and negative risk factors for atherosclerotic cardiovascular disease (ASCVD). New research, however, has challenged the widely held belief that high HDL-C levels are atheroprotective and is showing that both low and high plasma HDL-C levels confer an increased risk of ASCVD. Furthermore, it is disputing the widely cited mechanism involved in reverse cholesterol transport. This review explores the evolution of cholesterol research starting with the Gofman and Framingham studies, the development of traditional and emerging lipid-lowering therapies, and the role of reverse cholesterol transport in HDL cardioprotection.
鉴于胆固醇在许多生命必需的生化过程中所起的作用,它仍然是一个深入研究的课题。在所有血浆脂质中,胆固醇具有独特性,因为它是类固醇生成分子的前体,其中一些分子调节新陈代谢,并且其以低密度和高密度脂蛋白胆固醇(HDL-C)形式存在的血液浓度分别是动脉粥样硬化性心血管疾病(ASCVD)的正性和负性危险因素。然而,新的研究对广泛持有的高HDL-C水平具有抗动脉粥样硬化保护作用这一观点提出了挑战,并表明血浆HDL-C水平无论是低还是高都会增加ASCVD的风险。此外,它还对广泛引用的胆固醇逆向转运机制提出了质疑。本综述探讨了从戈夫曼和弗雷明汉姆研究开始的胆固醇研究的演变、传统和新兴降脂疗法的发展以及胆固醇逆向转运在HDL心脏保护中的作用。